Insiders Bet Big on Robinhood and GeneDx

Fresh filings show a clear split: smart money is piling into fintech and genomics, while a hedge fund board member quietly exits Twilio.

Robinhood piles up buying. Ribbit Capital, a board-level VC backer, filed $75M in HOOD purchases over the past two weeks. Director Meyer Malka joined in, filing a separate $20M buy on June 9. The trades spanned prices from $80 to $83 per share. Two insiders buying in rapid succession is a strong signal of near-term confidence.

GeneDx draws repeated bets. Casdin Capital, a 10% owner with board representation, filed $93M worth of WGS purchases since mid-May. Corvex Management added another $12M alongside. The buying intensified recently, with filings as late as June 8, suggesting conviction is growing — not fading.

Twilio insider cashes out. Hedge fund board member Andrew Stafman filed $315M in TWLO sales across two trades in May. He sold 1M shares at $184 and 675K shares at $193. That's a significant exit from a board-level position.

The contrast is sharp: insiders are adding to stakes in high-growth genomics and fintech, while trimming exposure to a communications software name that has run hard this year.